Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?

Dr. Tarantino was invited to share insights with fellow physicians by responding to a survey specifically tailored for Canadian oncologists. The survey focused on addressing key questions related to 2L HER2+ Breast Cancer and the DESTINY BREAST Trial, and Dr. Tarantino provides his expert responses here.

Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?

Q2: What are the steps you take to optimally manage ILD for patients on T-DXd (The 5 S Rules)?

Q3: Any other AEs to be on a look out for?

Q4: What is the impact of DESTINY BREAST trial on triple-negative breast cancer?

Paolo Tarantino is a MD and researcher at the European Institute of Oncology (Milan, Italy) and clinical research fellow at the Dana-Farber Cancer Institute (Boston, MA). His main areas of research are breast cancer, HER2 oncogene and antibody-drug conjugates.

Dr. Tarantino is a leading researcher in the field of breast cancer, with over 50 papers published on the topic. He’s currently pursuing an advanced research fellowship at Dana-Farber Cancer Institute and at Harvard Medical School (Boston, MA).

He is also concomitantly pursuing a PhD in clinical research at the University of Milan.

His research focuses on the study of the HER2 oncoprotein, the emerging HER2-low subgroup of breast tumors and the development of novel antibody-drug conjugates to treat every subtype of breast cancer.

This is a joint educational initiative between the McPeak-Sirois Group and oncoXchange

Supporter acknowledgment: This series is sponsored by AstraZeneca Canada Inc. and is intended for healthcare practitioners only.